solo per uso di ricerca
N. Cat.: S1949
Struttura chimica
| Linee cellulari | Tipo di saggio | Concentrazione | Tempo di incubazione | Formulazione | Descrizione dell'attività | PMID |
|---|---|---|---|---|---|---|
| HT22 cells | Function assay | Neuroprotective activity in mouse HT22 cells assessed as prevention from glutamate-induced oxidative cell death by MTS assay, PD50=0.797 μM | ||||
| HeLa cell | Cytotoxicity assay | Cytotoxicity against HeLa cell lines, EC50=3.7 μM | ||||
| PaCa2 cell | Proliferation assay | Antiproliferative activity against human pancreatic carcinoma Mia PaCa2 cell line by colorimetric assay, IC50=6.2 μM | ||||
| HT-29 cells | Cytotoxicity assay | 72 h | Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTS assay, IC50=9.69 μM | |||
| DU145 cells | Cytotoxicity assay | 72 h | Cytotoxicity against human DU145 cells assessed as growth inhibition after 72 hrs by MTS assay, IC50=9.86 μM | |||
| MDA-MB-231 cells | Cytotoxicity assay | 72 h | Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTS assay, IC50=12.68 μM | |||
| human A2058 cells | Cytotoxicity assay | Cytotoxicity against human A2058 cells assessed as inhibition of formazan formation at day 5 by measuring absorbance at 430 nm, IC50=13.4 μM | ||||
| SAS cells | Cytotoxicity assay | 48 h | Cytotoxicity against human SAS cells assessed as reduction in cell viability after 48 hrs by MTT assay, IC50=14 μM | |||
| HaCaT cells | Function assay | 48 h | Antihyperproliferative activity against human HaCaT cells assessed as inhibition of cell growth after 48 hrs by phase contrast microscopy, IC50=15.8 μM | |||
| HeLa cells | Cytotoxicity assay | 48 h | Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay, IC50=18 μM | |||
| CRL2796 cells | Cytotoxicity assay | Cytotoxicity against human CRL2796 cells assessed as inhibition of formazan formation at day 4 by measuring absorbance at 430 nm, IC50=21 μM | ||||
| HL60 cells | Function assay | 50 μM | Induction of necrosis in intact human HL60 cells assessed as cytosolic LDH release at 50 uM | |||
| Clicca per visualizzare più dati sperimentali sulle linee cellulari | ||||||
| Peso molecolare | 172.18 | Formula | C11H8O2 |
Conservazione (Dalla data di ricezione) | 3 years-20°C(in the dark) powder |
|---|---|---|---|---|---|
| N. CAS | 58-27-5 | Scarica SDF | Conservazione delle soluzioni stock | Le soluzioni sono instabili. Preparare al momento o acquistare formati piccoli e preconfezionati. Riconfezionare al ricevimento. | |
| Sinonimi | NSC 4170 | Smiles | CC1=CC(=O)C2=CC=CC=C2C1=O | ||
|
In vitro |
DMSO
: 34 mg/mL
(197.46 mM)
Ethanol : 34 mg/mL Water : Insoluble |
|
In vivo |
|||||
Passo 1: Inserire le informazioni di seguito (Consigliato: Un animale aggiuntivo per tenere conto della perdita durante l'esperimento)
Passo 2: Inserire la formulazione in vivo (Questo è solo il calcolatore, non la formulazione. Contattateci prima se non c'è una formulazione in vivo nella sezione Solubilità.)
Risultati del calcolo:
Concentrazione di lavoro: mg/ml;
Metodo per preparare il liquido master di DMSO: mg farmaco predissolto in μL DMSO ( Concentrazione del liquido master mg/mL, Vi preghiamo di contattarci prima se la concentrazione supera la solubilità del DMSO del lotto del farmaco. )
Metodo per preparare la formulazione in vivo: Prendere μL DMSO liquido master, quindi aggiungereμL PEG300, mescolare e chiarire, quindi aggiungereμL Tween 80, mescolare e chiarire, quindi aggiungere μL ddH2O, mescolare e chiarire.
Metodo per preparare la formulazione in vivo: Prendere μL DMSO liquido master, quindi aggiungere μL Olio di mais, mescolare e chiarire.
Nota: 1. Si prega di assicurarsi che il liquido sia limpido prima di aggiungere il solvente successivo.
2. Assicurarsi di aggiungere il/i solvente/i in ordine. È necessario assicurarsi che la soluzione ottenuta, nell'aggiunta precedente, sia una soluzione limpida prima di procedere all'aggiunta del solvente successivo. Metodi fisici come il vortex, gli ultrasuoni o il bagno d'acqua calda possono essere utilizzati per facilitare la dissoluzione.
| Targets/IC50/Ki |
Cdc25 phosphatase
DNA polymerase γ
|
|---|---|
| In vitro |
Menadione (Vitamin K3) prevents mitochondrial Ca(2+) uptake in normal pancreatic acinar cells, which permits rapid spread of Ca(2+) throughout the cell. Its-induced mitochondrial depolarisation is due to induction of the permeability transition pore. At nontoxic concentration, this compound results in a brief activation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) in the RALA255-10G rat hepatocyte cell line. It is equipotent against multidrug-resistant and parental leukemia cell lines with IC50 values of 13.5 mM and 18 mM, respectively. The compound inhibits the incorporation of radioactive thymidine, uridine and amino acids into DNA, RNA and protein, respectively, in three humancancer cell lines. At 1-20 mM, it dose- and time-dependently inhibits cell proliferation of AR4-2J cells. A concentration of 100 mM causes rapid cell death. This level (100 mM) induces DNA smear in electrophoresis indicative of necrosis, while lower concentrations (10-20 mM) induces a DNA ladder indicative of apoptosis. Concentrations of 1-20 mM induce wild-type P53, whereas 100 mM has a minor effect on wild-type P53. Treatment with it clearly affects the mitochondrial function of Jurkat T cells by inducing a collapse of the inner transmembrane potential (DeltaPsi(m)) and a decrease in inner membrane mass, which could be completely reversed by N-acetylcysteine. |
Riferimenti |
|
| Metodi | Biomarcatori | Immagini | PMID |
|---|---|---|---|
| Western blot | p-JNK / JNK / p-c-Jun / c-Jun / p-ERK / ERK Cyclin B1 / CDK1 / CDC25C c-Fos / HO-1 |
|
20578144 |
(dati da https://clinicaltrials.gov, aggiornato il 2020-01-29)
| Numero NCT | Reclutamento | Condizioni | Sponsor/Collaboratori | Data di inizio | Fasi |
|---|---|---|---|---|---|
| NCT04247087 | COMPLETED | Coronary Calcification |
Instituto Mexicano del Seguro Social |
2017-09-07 | |
| NCT03547895 | COMPLETED | Decompensated Cirrhosis |
Zagazig University |
2015-06-01 | |
| NCT01094444 | COMPLETED | Folliculitis |
Per Pfeiffer |
2010-05 | PHASE2 |
| NCT01393821 | COMPLETED | Dermatologic Complications; Malignant Neoplasm; Pain |
Mayo Clinic |
2012-01-23 | |
| NCT01094444 | Completed | Folliculitis |
Per Pfeiffer|Odense University Hospital |
2010-05 | Phase 2 |
| NCT00656786 | COMPLETED | EGFR Inhibitor-associated Rash |
Spectrum Pharmaceuticals, Inc |
2008-04-03 | PHASE1 |